DrugCentral: online drug compendium
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
DrugCentral (http://drugcentral.org) is an open-access online drug compendium. DrugCentral integrates structure, bioactivity, regulatory, pharmacologic actions and indications for active pharmaceutical ingredients approved by FDA and other regulatory agencies. Monitoring of regulatory agencies for new drugs approvals ensures the resource is up-to-date. DrugCentral integrates content for active ingredients with pharmaceutical formulations, indexing drugs and drug label annotations, complementing similar resources available online. Its complementarity with other online resources is facilitated by cross referencing to external resources. At the molecular level, DrugCentral bridges drug-target interactions with pharmacological action and indications. The integration with FDA drug labels enables text mining applications for drug adverse events and clinical trial information. Chemical structure overlap between DrugCentral and five online drug resources, and the overlap between DrugCentral FDA-approved drugs and their presence in four different chemical collections, are discussed. DrugCentral can be accessed via the web application or downloaded in relational database format.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are 217 drugs annotated in DrugCentral10 as acting through 125 (T) ion channels for the MoA9.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chemical structures were manually assigned to 140 of the latest veterinary drugs, and molecular descriptors and structure depictions were computed per DrugCentral workflow (1).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“DrugCentral has been a public digital database aggregating drug information since 2016 (1).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
KEGG for integration and interpretation of large-scale molecular data sets
Kanehisa, M., Goto, S., Sato, Y., Furumichi, M., & Tanabe, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr988 · Cited by 4,848 · cited 2×
“The following resources matched our above inclusion criteria: the ChEMBL database (1), the Guide to Pharmacology (2) and KEGG Drug (3).”
BackgroundMethodThe unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427 · cited 1×
“) to which the API or its active metabolite binds directly, to exert the therapeutic drug action (22).”
BackgroundSelf-citationDrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993 · cited 10×
“The overlap matrix was computed for DrugCentral, in comparison with the following drugfocused resources: the NIH Center for Chemical Genomics (NCGC) pharmaceutical collection (11), DrugBank (12), the IDAAPM database (13), the phase 4 drugs subset from the ChEMBL 21 release (1) and the e-Drug3D database (14).”
MethodInfluentialThe ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,492 · cited 5×
“Mechanism of action annotations in DrugCentral are aggregated from several expert curated resources: ChEMBL database (1), Guide to Pharmacology (2), KEGG Drug (3), as well as manual curations extracted from drug labels and literature.”
BackgroundMethodInfluentialThe SIDER database of drugs and side effects
Kuhn, M., Letunic, I., Jensen, L. J., & Bork, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1075 · Cited by 1,451 · cited 3×
“Drug adverse events from FDA AERS database (https://open.fda.gov/) and SIDER (21) will be used to enhance the drug safety profile of existing drug reports.”
BackgroundSouthan, C., Sharman, J. L., Benson, H. E., Faccenda, E., Pawson, A. J., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1037 · Cited by 1,035 · cited 3×
“Quantitative bioactivity data are aggregated from multiple sources including: ChEMBLDb (1) (58.73% of the records); DrugMatrix (23) (15.95%); WOMBAT-PK (24) (13.9%); Guide to Pharmacology (2) (5.29%); PDSP (25) (3.41%); scientific literature (2.35%); and drug labels (0.36%), respectively.”
BackgroundMethodInfluentialCalculating log Poct from structures
Leo, A. J. (1993) · Chemical Reviews · doi:10.1021/cr00020a001 · Cited by 695
Dalby, A., Nourse, J. G., Hounshell, W. D., Gushurst, A. K. I., Grier, D. L., Leland, B. A., & Laufer, J. (1992) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00007a012 · Cited by 642 · cited 1×
“A multistep manual curation and validation process was employed to collect, record and store correct chemical information for API molecular structures in the MDL (‘Molecular Design Limited’) MOL format (8).”
Method
Cited by
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Self-citationHarding, S. D., Sharman, J. L., Faccenda, E., Southan, C., Pawson, A. J., Ireland, S., Gray, A. J. G., Bruce, L., Alexander, S. P. H., Anderton, S., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1121 · Cited by 1,646
“The same figure shows that in the case of both DrugBank (18) and DrugCentral (19) there are ∼5500 CIDs unique to just GtoPdb.”
BackgroundZhang, P., Zhang, D., Zhou, W., Wang, L., Wang, B., Zhang, T., & Li, S. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad518 · Cited by 675
“Thus, the network relationships also include those between compounds or natural products and their relevant molecular targets mined from databases such as HIT [36],TCMGeneDIT [37],DrugCentral [38] and DrugBank [39].”
BackgroundSystematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
Li, Y. H., Yu, C. Y., Li, X. X., Zhang, P., Tang, J., Yang, Q., Fu, T., Zhang, X., Cui, X., Tu, G., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1076 · Cited by 523
“In particular, a number of freely accessible databases complementarily provide comprehensive information about the therapeutic targets with additional information about the clinical trial drugs (11–13), biomarkers (11), molecular activity data (11,13–15), drug-binding sites (16,17) and targetaffiliated biological path…”
BackgroundMachine learning approaches and databases for prediction of drug–target interaction: a survey paper
Bagherian, M., Sabeti, E., Wang, K., Sartor, M. A., Nikolovska-Coleska, Z., & Najarian, K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz157 · Cited by 429
“DrugCentral is a comprehensive database that focuses on drug collection [ 285, 286].”
BackgroundJarada, T. N., Rokne, J. G., & Alhajj, R. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00450-7 · Cited by 384
“A repository of drug-related information, such as chemical structure for drugs Drug Centr al [83] A repository of drug-related information such as chemical structure and biological activities PubCh em[84] A repository of chemical substances and their biological activities Prote in Data Bank…”
BackgroundUnexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378
Self-citationTarget identification among known drugs by deep learning from heterogeneous networks
Zeng, X., Zhu, S., Lu, W., Liu, Z., Huang, J., Zhou, Y., Fang, J., Huang, Y., Guo, H., Li, L., et al. (2020) · Chemical Science · doi:10.1039/c9sc04336e · Cited by 357
Erratum: Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 311
Self-citationA standard database for drug repositioning
Brown, A. S., & Patel, C. J. (2017) · Scientific Data · doi:10.1038/sdata.2017.29 · Cited by 305
“More information about the accuracy of the annotations can be found in the methods, as well as in publications describing the Medical Text Indexer and the Observational Medical Outcomes Partnership (F1 measures of 0.55 and 0.98, used in AACT and DrugCentral respectively) 17 – 19 , 23 .”
InfluentialInformation retrieval and text mining technologies for chemistry
Krallinger, M., Rabal, O., Lourenço, A., Oyarzabal, J., & Valencia, A. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00851 · Cited by 281
Pharos: collating protein information to shed light on the druggable genome
Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J., Jensen, L. J., Karlsson, A., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1072 · Cited by 279
“DrugCentral (11) aggregates targetdisease information, drug target bioactivity data, which are used to categorize Tclin and Tchem, and feeds into TCRD.”
BackgroundSelf-citationNetwork-Based Methods for Prediction of Drug-Target Interactions
Wu, Z., Li, W., Liu, G., & Tang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01134 · Cited by 237
“Over the past decade, various computational methods were developed for drug repurposing (Vanhaelen et al., 2017).”
MethodTowards reproducible computational drug discovery
Schaduangrat, N., Lampa, S., Simeon, S., Gleeson, M. P., Spjuth, O., & Nantasenamat, C. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-0408-x · Cited by 208
DrugCentral 2021 supports drug discovery and repositioning
Avram, S., Bologa, C. G., Holmes, J., Bocci, G., Wilson, T. B., Nguyen, D.-T., Curpan, R., Halip, L., Bora, A., Yang, J. J., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa997 · Cited by 189
“First introduced and published in the 2017 NAR database issue (1), Drug-Central reconciles the basic scientist’s understanding of the ‘drug’ concept (active pharmaceutical ingredient) with the view of the patient and healthcare practitioner (pharmaceutical formulation).”
BackgroundInfluentialSelf-citationTransforming Clinical Research: The Power of High-Throughput Omics Integration
Vitorino, R. (2024) · Proteomes · doi:10.3390/proteomes12030025 · Cited by 183
“An exemplary initiative in this area is NeDRexDB [127], which integrates data from a variety of biomedical databases such as OMIM [128], DisGeNET [129], UniProt [112], NCBI gene info, IID [130], Reactome [131], MONDO [132], DrugBank [133] and DrugCentral [134].”
BackgroundLow, Z. Y., Farouk, I. A., & Lal, S. K. (2020) · Viruses · doi:10.3390/v12091058 · Cited by 180
A review of biomedical datasets relating to drug discovery: a knowledge graph perspective
Bonner, S., Barrett, I. P., Ye, C., Swiers, R., Engkvist, O., Bender, A., Hoyt, C. T., & Hamilton, W. L. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac404 · Cited by 196
“DrugCentral is a resource containing information on drugs and other pharmaceuticals [118].”
BackgroundWikidata as a knowledge graph for the life sciences
Waagmeester, A., Stupp, G. S., Burgstaller-Muehlbacher, S., Good, B. M., Griffith, M., Griffith, O. L., Hanspers, K., Hermjakob, H., Hudson, T., Hybiske, K., et al. (2020) · eLife · doi:10.7554/elife.52614 · Cited by 188
Changing Trends in Computational Drug Repositioning
Yella, J. K., Yaddanapudi, S., Wang, Y., & Jegga, A. G. (2018) · Pharmaceuticals · doi:10.3390/ph11020057 · Cited by 166
Evolving scenario of big data and Artificial Intelligence (AI) in drug discovery
Tripathi, M. K., Nath, A., Singh, T. P., Ethayathulla, A. S., & Kaur, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10256-w · Cited by 138
Ursu, O., Holmes, J., Bologa, C. G., Yang, J. J., Mathias, S. L., Stathias, V., Nguyen, D.-T., Schürer, S., & Oprea, T. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky963 · Cited by 142
“org) was first made available to the public in 2016 and published in the 2017 NAR Database issue (1).”
BackgroundSelf-citationKim, H., Kim, E., Lee, I., Bae, B., Park, M., & Nam, H. (2020) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-020-0049-y · Cited by 131
“From DailyMed and DrugCentral, we can obtain overall drug information, including original drug indications [285-287].”
MethodA cell-type-specific atlas of the inner ear transcriptional response to acoustic trauma
Milon, B. C., Shulman, E. D., So, K. S., Cederroth, C. R., Lipford, E. L., Sperber, M., Sellon, J. B., Sarlus, H., Pregernig, G., Shuster, B., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109758 · Cited by 123
“By intersecting the noise-induced gene expression changes in our combined datasets with DrugCentral (Ursu et al., 2017), we identified metformin as the top-ranking candidate therapeutic (Table S7).”
InfluentialDrug-drug interactions prediction based on deep learning and knowledge graph: A review
Luo, H., Yin, W., Wang, J., Zhang, G., Liang, W., Luo, J., & Yan, C. (2024) · iScience · doi:10.1016/j.isci.2024.109148 · Cited by 129
Drug Repositioning in Glioblastoma: A Pathway Perspective
Tan, S. K., Jermakowicz, A., Mookhtiar, A. K., Nemeroff, C. B., Schürer, S. C., & Ayad, N. G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00218 · Cited by 116
“Importantly, several well annotated databases of approved drugs and compounds in clinical trials are publicly available including ChEMBL (Bento et al., 2014), DrugBank (Wishart et al., 2006), and DrugCentral (Ursu et al., 2017).”
BackgroundCavasotto, C. N., & Filippo, J. I. D. (2020) · Molecular Informatics · doi:10.1002/minf.202000115 · Cited by 120
Graph Neural Networks in Modern AI-Aided Drug Discovery
Zhang, O., Lin, H., Zhang, X., Wang, X., Wu, Z., Ye, Q., Zhao, W., Wang, J., Ying, K., Kang, Y., et al. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00461 · Cited by 139
Yang, J., Tian, S., Zhao, J., & Zhang, W. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105034 · Cited by 112
Self-citationScreening of Therapeutic Agents for COVID-19 Using Machine Learning and Ensemble Docking Studies
Batra, R., Chan, H., Kamath, G., Ramprasad, R., Cherukara, M. J., & Sankaranarayanan, S. K. R. S. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c02278 · Cited by 101
Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery
Conflitti, P., Lyman, E. R., Sansom, M. S. P., Hildebrand, P. W., Gutiérrez‐de‐Terán, H., Carloni, P., Ansell, T. B., Yuan, S., Barth, P., Robinson, A. S., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01083-3 · Cited by 119
“The δ-opioid receptor is the most targeted subfamily with 22 pathway-biased ligands, followed by the orphan receptor GPR84 with 21 molecules, and D 2 R and adenosine A 3 (A 3 R) receptors with 15 each 3,229,230 .”
DrugCentral 2023 extends human clinical data and integrates veterinary drugs
Avram, S., Wilson, T. B., Curpan, R., Halip, L., Borota, A., Bora, A., Bologa, C. G., Holmes, J., Knockel, J., Yang, J. J., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1085 · Cited by 101
Self-citationSuperDRUG2: a one stop resource for approved/marketed drugs
Siramshetty, V. B., Eckert, O. A., Gohlke, B.-O., Goede, A., Chen, Q., Devarakonda, P., Preißner, S., & Preißner, R. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1088 · Cited by 103
“A recent addition to the league of publicly accessible drug databases is DrugCentral (9) which serves as an online drug compendium with a special focus on active pharmaceutical ingredients that are approved by FDA and other drug regulatory agencies.”
BackgroundKG-COVID-19: A Framework to Produce Customized Knowledge Graphs for COVID-19 Response
Reese, J. T., Unni, D., Callahan, T. J., Cappelletti, L., Ravanmehr, V., Carbon, S., Shefchek, K. A., Good, B. M., Balhoff, J. P., Fontana, T., et al. (2021) · Patterns · doi:10.1016/j.patter.2020.100155 · Cited by 92
Morris, J. H., Soman, K., Akbas, R. E., Zhou, X., Smith, B., Meng, E. C., Huang, C. C., Cerono, G., Schenk, G., Rizk-Jackson, A., et al. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad080 · Cited by 99
Zuo, H., Zhang, Q., Su, S.-B., Chen, Q., Yang, F. Q., & Yuanjia, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-29764-1 · Cited by 96
In Silico Toxicology Data Resources to Support Read-Across and (Q)SAR
Pawar, G. V., Madden, J. C., Ebbrell, D. J., Firman, J. W., & Cronin, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00561 · Cited by 97
“DrugCentral (Ursu et al., 2017) is another drug compendium covering 4,531 active ingredients, 3,807 small molecules, 279 biologics, 445 other compounds, 77,484 FDA drug labels, 34,192 prescription only drug labels, 43,292 OTC drug labels, and 97,271 pharmaceutical formulations with FDA drug labels.”
BackgroundWang, Z., Zhou, M., & Arnold, C. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa437 · Cited by 90
Nelson, C. A., Butte, A. J., & Baranzini, S. E. (2019) · Nature Communications · doi:10.1038/s41467-019-11069-0 · Cited by 85
Druggable genome and precision medicine in cancer: current challenges
Dupont, C., Riegel, K., Pompaiah, M., Juhl, H. H., & Rajalingam, K. (2021) · FEBS Journal · doi:10.1111/febs.15788 · Cited by 86
Essegian, D., Khurana, R., Stathias, V., & Schürer, S. C. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100128 · Cited by 74
“8 Cell Reports Medicine 1, 100128, October 20, 2020 nib, vandetanib, bosutinib, sorafenib, and sunitinib all inhibit understudied kinases in the low nanomolar range (including SBK3, STK32A, RIOK1, CDK15, and CSNK1A1L), one of which is Tdark (CSNK1A1L).(1) Thus, it is possible that some therapeutic effect or anti-cance…”
BackgroundMetapath-aggregated heterogeneous graph neural network for drug–target interaction prediction
Li, M., Cai, X., Xu, S., & Ji, H. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac578 · Cited by 88
A machine learning platform to estimate anti-SARS-CoV-2 activities
Govinda, K. C., Bocci, G., Verma, S., Hassan, M. M., Holmes, J., Yang, J. J., Sirimulla, S., & Oprea, T. I. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00335-w · Cited by 82
“SMILES were retrieved from DrugCentral whenever possible, otherwise the original SMILES strings were retained.”
MethodInfluentialSelf-citationWang, X., Cheng, Y., Yang, Y., Yu, Y., Li, F., & Peng, S. (2023) · Nature Machine Intelligence · doi:10.1038/s42256-023-00640-6 · Cited by 84
“To improve the efficiency of drug discovery, a great number of researchers have devoted to developing or leveraging deep learning to speed up its intermediate steps, such as molecular property prediction [3-4], drug-target interaction (DTI) predictions [5-8], and drug-drug interaction (DDI) predictions [9-11].”
Solís, R. R., Mena, I. F., Nadagouda, M. N., & Dionysiou, D. D. (2019) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2019.121340 · Cited by 76
A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome
Misselbeck, K., Parolo, S., Lorenzini, F., Savoca, V., Leonardelli, L., Bora, P., Morine, M. J., Mione, M., Domenici, E., & Priami, C. (2019) · Nature Communications · doi:10.1038/s41467-019-13208-z · Cited by 75
HyperFoods: Machine intelligent mapping of cancer-beating molecules in foods
Veselkov, K., Gonzalez, G., Aljifri, S., Galea, D., Mirnezami, R., Youssef, J., Bronstein, M., & Laponogov, I. (2019) · Scientific Reports · doi:10.1038/s41598-019-45349-y · Cited by 71
Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors
Akhavanfard, S., Padmanabhan, R., Yehia, L., Cheng, F., & Eng, C. (2020) · Nature Communications · doi:10.1038/s41467-020-16067-1 · Cited by 73
Drug target ontology to classify and integrate drug discovery data
Lin, Y., Mehta, S., Küçük-McGinty, H., Turner, J. P., Vidovic, D., Forlin, M., Koleti, A., Nguyen, D.-T., Jensen, L. J., Guha, R., et al. (2017) · Journal of Biomedical Semantics · doi:10.1186/s13326-017-0161-x · Cited by 69
“In some cases, targets have been manually migrated to Tchem through human curation, based on small molecule activities from sources other than ChEMBL or DrugCentral [34].”
MethodSelf-citationROBOKOP KG and KGB: Integrated Knowledge Graphs from Federated Sources
Bizon, C., Cox, S., Balhoff, J. P., Kebede, Y., Wang, P., Morton, K. D., Fecho, K., & Tropsha, A. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00683 · Cited by 76
Zheng, Y., Peng, H., Zhang, X., Zhao, Z., Gao, X., & Li, J. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3214-6 · Cited by 69
Drug Repurposing Using Deep Embeddings of Gene Expression Profiles
Donner, Y., Kazmierczak, S., & Fortney, K. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00284 · Cited by 73
Computational Drug Repositioning: Current Progress and Challenges
Ko, Y. (2020) · Applied Sciences · doi:10.3390/app10155076 · Cited by 67
Bakal, G., Talari, P., Kakani, E., & Kavuluru, R. (2018) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2018.05.003 · Cited by 63
“approved drugs and corresponding indications collected from the regularly updated DrugCentral platform [35].”
Causal network models of SARS-CoV-2 expression and aging to identify candidates for drug repurposing
Belyaeva, A., Cammarata, L., Radhakrishnan, A., Squires, C., Yang, K. D., Shivashankar, G. V., & Uhler, C. (2021) · Nature Communications · doi:10.1038/s41467-021-21056-z · Cited by 63
Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19
Bocci, G., Bradfute, S. B., Ye, C., Garcia, M. J., Parvathareddy, J., Reichard, W., Surendranathan, S., Bansal, S., Bologa, C., Perkins, D. J., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00131 · Cited by 61
Self-citationData Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs
Douguet, D. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00462 · Cited by 61
NCATS Inxight Drugs: a comprehensive and curated portal for translational research
Siramshetty, V. B., Grishagin, I. V., Nguyễn, Ð.-T., Peryea, T., Skovpen, Y., Stroganov, O. V., Katzel, D. A., Sheils, T. K., Jadhav, A., Mathé, E. A., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab918 · Cited by 63
Serine protease inhibitors to treat inflammation: a patent review (2011-2016)
Soualmia, F., & Amri, C. E. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1406478 · Cited by 56
Current advances in ligand‐based target prediction
Yang, S., Ye, Q., Ding, J., Yin, M., Lü, A., Chen, X., Hou, T., & Cao, D. (2020) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1504 · Cited by 61
Partner-Specific Drug Repositioning Approach Based on Graph Convolutional Network
Sun, X., Wang, B., Zhang, J., & Li, M. (2022) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2022.3194891 · Cited by 53
“We subsequently rank all the candidate drugs by the computed predictionscoresforeachdisease,andverifythepredictedtop10 potential drug-disease associations in acknowledged CTD [36], PubChem, 1 and DrugCentral [37] databases.”
Open chemoinformatic resources to explore the structure, properties and chemical space of molecules
González-Medina, M., Naveja, J. J., Sánchez‐Cruz, N., & Medina‐Franco, J. L. (2017) · RSC Advances · doi:10.1039/c7ra11831g · Cited by 53
Exploring the dark genome: implications for precision medicine
Oprea, T. I. (2019) · Mammalian Genome · doi:10.1007/s00335-019-09809-0 · Cited by 50
Self-citationKG-MTL: Knowledge Graph Enhanced Multi-Task Learning for Molecular Interaction
Ma, T., Lin, X., Song, B., Yu, P. S., & Zeng, X. (2022) · IEEE Transactions on Knowledge and Data Engineering · doi:10.1109/tkde.2022.3188154 · Cited by 84
“2) DrugCentral contains 9,477 drug-target interactions with 1,427 drugs and 1,106 targets [41].”
BackgroundSurvey of Similarity-Based Prediction of Drug-Protein Interactions
Wang, C., & Kurgan, L. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190808154841 · Cited by 52
KG-Hub—building and exchanging biological knowledge graphs
Caufield, J. H., Putman, T., Schaper, K., Unni, D., Hegde, H., Callahan, T. J., Cappelletti, L., Moxon, S. A. T., Ravanmehr, V., Carbon, S., et al. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad418 · Cited by 55
Awad, I. E., Abu‐Saleh, A. A. A., Sharma, S., Yadav, A., & Poirier, R. A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1835721 · Cited by 48
Targeted protein degradation in the transmembrane and extracellular space
Zhu, R., Zhang, H., & Chen, P. R. (2025) · Science · doi:10.1126/science.adx5094 · Cited by 50
Aguirre‐Plans, J., Piñero, J., Sanz, F., Furlong, L. I., Fernández‐Fuentes, N., Oliva, B., & Güney, E. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.02.027 · Cited by 49
“0 now allows to search by a drug in addition to a phenotype and returns a list of drug-target associations integrated from DrugBank [17], DGIdb [18], DrugCentral [19] and ChEMBL [20] (see details in Supplementary Material).”
BackgroundMolecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing
Madugula, S. S., John, L., Nagamani, S., Gaur, A. S., Poroikov, V., & Sastry, G. N. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104856 · Cited by 48
Network machine learning maps phytochemically rich “Hyperfoods” to fight COVID-19
Laponogov, I., Gonzalez, G., Shepherd, M., Qureshi, A., Veselkov, D. A., Charkoftaki, G., Vasiliou, V., Youssef, J., Mirnezami, R., Bronstein, M. M., et al. (2021) · Human Genomics · doi:10.1186/s40246-020-00297-x · Cited by 46
Artificial Intelligence-Guided De Novo Molecular Design Targeting COVID-19
Srinivasan, S., Batra, R., Chan, H., Kamath, G., Cherukara, M. J., & Sankaranarayanan, S. K. R. S. (2021) · ACS Omega · doi:10.1021/acsomega.1c00477 · Cited by 42
NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study
Reese, J., Coleman, B., Chan, L., Blau, H., Callahan, T. J., Cappelletti, L., Fontana, T., Bradwell, K. R., Harris, N. L., Casiraghi, E., et al. (2022) · Virology Journal · doi:10.1186/s12985-022-01813-2 · Cited by 41
“…hypertension, hypertensive kidney disease, ischemic heart disease, lupus, malignant neoplasm (lymphoid hematopoietic related tissue), neoplasm, nicotine dependence, nonhypertensive chronic kidney disease, nonischemic heart disease, other liver disease, portal hypertension, psoriasis, rheumatoid…”
Pan-assay interference compounds (PAINS) that may not be too painful for chemical biology projects
Lagorce, D., Oliveira, N., Miteva, M. A., & Villoutreix, B. O. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.05.017 · Cited by 41
Serrablo-Torrejon, I., López‐Valenciano, A., Ayuso, M., Horton, E., Mayo, X., Medina‐Gómez, G., Liguori, G. A., & Jiménez, A. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00640-2 · Cited by 40
Clyde, A., Liu, X., Brettin, T. S., Yoo, H., Partin, A., Babuji, Y., Blaiszik, B. J., Mohd-Yusof, J., Merzky, A., Turilli, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28785-9 · Cited by 44
CORUM in 2024: protein complexes as drug targets
Steinkamp, R., Tsitsiridis, G., Brauner, B., Montrone, C., Fobo, G., Frishman, G., Avram, S. I., Oprea, T. I., & Ruepp, A. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1033 · Cited by 41
Self-citationLagarde, N., Rey, J., Gyulkhandanyan, A., Tufféry, P., Miteva, M. A., & Villoutreix, B. O. (2018) · Oncotarget · doi:10.18632/oncotarget.25966 · Cited by 37
“10, the DrugCentral online compendium [28] and the “approved” SuperDrug2 database version 2.”
BackgroundXuan, P., Chen, B., Zhang, T., & Yang, Y. X. (2020) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2020.2989765 · Cited by 36
Sustainable data and metadata management at the BD2K-LINCS Data Coordination and Integration Center
Stathias, V., Koleti, A., Vidović, D., Cooper, D. J., Jagodnik, K. M., Terryn, R., Forlin, M., Chung, C., Torre, D., Ayad, N. G., et al. (2018) · Scientific Data · doi:10.1038/sdata.2018.117 · Cited by 36
Kropiwnicki, E., Evangelista, J. E., Stein, D. J., Clarke, D. J. B., Lachmann, A., Kuleshov, M. V., Jeon, M., Jagodnik, K. M., & Ma’ayan, A. (2021) · Database · doi:10.1093/database/baab017 · Cited by 37
Ruan, D., Ji, S., Yan, C. C., Zhu, J., Zhao, X., Yang, Y., Gao, Y., Zou, C., & Dai, Q. (2021) · Patterns · doi:10.1016/j.patter.2021.100390 · Cited by 43
“50 The drug-disease association information came from the Drug-Bank database (version 4.3), 30 Drug Central, 37 and repoDB.”
InfluentialLichtenberg, F. R. (2022) · Economics & Human Biology · doi:10.1016/j.ehb.2022.101124 · Cited by 34
Predicting adverse drug reactions of combined medication from heterogeneous pharmacologic databases
Zheng, Y., Peng, H., Zhang, X., Zhao, Z., Yin, J., & Li, J. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2520-8 · Cited by 33
Kneller, L. A., Zubiaur, P., Koller, D., Abad‐Santos, F., & Hempel, G. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01041-x · Cited by 33
Editorial: Drug Repositioning: Current Advances and Future Perspectives
Nishimura, Y., & Hara, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01068 · Cited by 33
An Overview of Computational Methods, Tools, Servers, and Databases for Drug Repurposing
Sarvagalla, S., Syed, S. B., & Coumar, M. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00025-0 · Cited by 36
Bustamante, C., Ochoa, R., Asela, C., & Muskus, C. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00230-y · Cited by 31
Assessing network-based methods in the context of system toxicology
Valls-Margarit, J., Piñero, J., Füzi, B., Cerisier, N., Taboureau, O., & Furlong, L. I. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1225697 · Cited by 30
“, 2018), and DrugCentral (10/03/2022) (Ursu et al., 2016).”
Fang, J., Cai, C., Chai, Y.-T., Zhou, J., Huang, Y., Gao, L., Wang, Q., & Cheng, F. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.020 · Cited by 31
“[19].”
BackgroundMethodResultInfluentialLiu, X., Zhang, W., Tong, X., Zhong, F., Li, Z. S., Xiong, Z., Xiong, J., Wu, X., Fu, Z., Tan, X., et al. (2023) · Journal of Cheminformatics · doi:10.1186/s13321-023-00711-1 · Cited by 37
“Here, the “real” samples were collected from DrugBank [74] (9662), DrugCentral [75] (4053), SuperDRUG2 [76] (3982), CDEK [77] (4421) and Cortellis (25,217, all compounds except those that have passed phase III clinical trials).”
BackgroundDescriptor-Driven de Novo Design Algorithms for DOCK6 Using RDKit
Matos, G. D. R., Pak, S., & Rizzo, R. C. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01031 · Cited by 30
In silico methods for drug-target interaction prediction
Ru, X., Xu, L., Wu, H., & Zou, Q. (2025) · Cell Reports Methods · doi:10.1016/j.crmeth.2025.101184 · Cited by 37
Evidence-Based Precision Oncology with the Cancer Targetome
Blucher, A., Choonoo, G., Kulesz-Martin, M. F., Wu, G., & McWeeney, S. K. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.006 · Cited by 29
Predicting Drug Targets from Heterogeneous Spaces using Anchor Graph Hashing and Ensemble Learning
Zheng, Y., Peng, H., Zhang, X., Gao, X., & Li, J. (2018) · International Joint Conference on Neural Networks (IJCNN) · doi:10.1109/ijcnn.2018.8489028 · Cited by 29
“The targets were obtained from DrugBank and DrugCentral [28].”
MethodComputational resources associating diseases with genotypes, phenotypes and exposures
Zhang, W., Zhang, H., Yang, H., Li, M., Xie, Z., & Li, W. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby071 · Cited by 28
“DrugBank and DrugCentral have become the referential drug data source for a number of well-known public databases such as PubChem [144], ChEMBL [94], PharmGKB [98], UniProt [145]and SuperTarget [146].”
BackgroundInfluentialBlucher, A., McWeeney, S. K., Stein, L. D., & Wu, G. (2019) · F1000Research · doi:10.12688/f1000research.19592.1 · Cited by 30
Khatami, S. G., Mubeen, S., Bharadhwaj, V. S., Kodamullil, A. T., Hofmann‐Apitius, M., & Domingo‐Fernándéz, D. (2021) · npj Systems Biology and Applications · doi:10.1038/s41540-021-00199-1 · Cited by 28
Rath, M. K., Wellnitz, J., Martin, H., Melo-Filho, C. C., Hochuli, J. E., Silva, G. M., Beasley, J.-M. T., Maxfield, T., Sessions, Z. L., Popov, K. I., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02446 · Cited by 28
Metadata
- Authors
- Ursu, O., Holmes, J., Knockel, J., Bologa, C. G., Yang, J. J., Mathias, S. L., Nelson, S. J., & Oprea, T. I.
- Affiliations
- University of New Mexico (US)
- Corresponding author
- Oprea, Tudor I.
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-26
- Volume
- 45
- Issue
- D1
- Pages
- D932-D939
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5210665
- OpenAlex
- W2539985226
- Cited by
- 323
- References
- 29
- Citations by year
- 2026: 23 · 2025: 39 · 2024: 34 · 2023: 39 · 2022: 26 · 2021: 31 · 2020: 45 · 2019: 40 · 2018: 27 · 2017: 17 · 2016: 2
- FWCI
- 26.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UNM’s Digital Repository (University of New Mexico) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- European Bioinformatics Institute
- National Institutes of Health
- U.S. Food and Drug Administration
- National Cancer Institute (U54CA189205, P30CA118100)
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- pharmacopoeia, active pharmaceutical ingredients, FDA-approved drugs, drug labels, drug-target interactions, pharmacological activity, drug indications, drug formulation, text mining, drug adverse events
- MeSH terms
- Drug Compounding, Drug Interactions, Drug Labeling, Pharmaceutical Preparations, Humans, United States, United States Food and Drug Administration, Drug Approval, Search Engine, Databases, Pharmaceutical, Drug-Related Side Effects and Adverse Reactions, Web Browser
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.